AI assistant
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2019
Jan 4, 2019
31071_dirs_2019-01-03_5f1d61ec-846c-47fd-86da-beb248e0b4f3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2019-01-01
Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-01 | Common Stock | A | 600000 | $0.00 | Acquired | 2142455 | Direct |
Footnotes
F1: Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of three predetermined performance goals related to the advancement of the Company's clinical and preclinical programs and business development that must be achieved within two years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole.
F2: Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.